The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1270
September 24, 2007
View Complete Issue         Table of Contents 2019 
Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria
September 24, 2007 (Issue: 1270)
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria
Article code: 1270c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.